FDA Alerts

This roundup of recent FDA approvals details the authorization of a new COVID-19 vaccine and options for lung and prostate cancer.

In an emergency use authorization, the FDA has approved a new COVID-19 home test for use with a prescription.

The US Food and Drug Administration has issued an emergency use authorization for a rapid, lateral flow antigen test that is the first over-the-counter at-home diagnostic test for COVID-19.

The first at-home COVID-19 collection kit has been approved for adults aged 18 years or older. Find out more about the kit here.

The US Food and Drug Administration advisory committee has voted 17 to 4 in favor of recommending the authorization the Pfizer/BioNTech COVID-19 mRNA vaccine (BNT162b2).

The panel released criteria for the emergency use of bamlanivimab in certain populations but has not indicated FDA approval of the treatment.

The FDA has expanded the indication of a previously approved influenza treatment to include post-exposure prophylaxis.

A prescription is no longer needed to obtain the topical lotion for treating head lice. This comes in response to the millions of cases of head lice reported annually by the Centers for Disease Control and...

The FDA has approved the first option for the treatment of adult and pediatric patients aged 12 years or older with COVID-19 who require hospitalization.

Nonsteroidal anti-inflammatory drugs put the fetus at risk for rare but serious kidney complications.